

SECOND ANNUAL FOX CHASE CANCER CENTER

ADVANCES IN THORACIC ONCOLOGY CONFERENCE

Featuring a Symposium on the 7th Edition
of the AJCC/UICC TNM Cancer Staging System
for Lung and Esophageal/GE Junction Cancers

FRIDAY, MARCH 26, 2010



LOCATION

DoubleTree Hotel Philadelphia

Broad Street at Locust | Philadelphia, PA 19107-5686

Sponsored by

FOX CHASE
CANCER CENTER
Philadelphia, PA

FOX CHASE
CANCER CENTER

Philadelphia, PA • www.fccc.edu

Telephone: 215-728-5358 • Fax: 215-214-8908

STATEMENT OF NEED

Evolving medical, surgical, radiation and diagnostic advances continue to expand our ability to diagnose, evaluate, stage and treat thoracic cancers and improve patient outcomes.

The Seventh Edition of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) TNM staging system has been published and will be in use officially starting January 1, 2010. The staging systems for lung cancer and esophageal cancer have been updated and significantly revised. This information will help physicians properly classify and stage patients and determine treatment recommendations for these patients. The morning session is designed specifically to address these changes and their clinical impact to physicians, administrators, billers, coders and tumor registrars. Case presentations and audience response technology will be a stimulating way to learn about the new staging systems and how to use them in practice.

A luncheon lecture will focus on the pretreatment evaluation of the mesothelioma patient. The specific tests that are needed for mesothelioma patients and indications for ordering those tests will be discussed.

Despite advances and new options, the management of Barrett's high-grade dysplasia (BHGD) and early esophageal cancer presents ongoing challenges in the clinical setting and has created some treatment dilemmas. During the afternoon session, we will feature a Point:Counterpoint discussion about when it is appropriate to treat with endoluminal therapy versus esophagectomy.

New chemotherapeutic options are emerging for lung disease. New ways to use existing agents are available. New tests for identifying patients who will respond to specific therapies continue to show promise. New personalized therapies for advanced and early stage lung cancer are evolving and expand available treatment options. We will present information that will help physicians evaluate the appropriate management of early stage and advanced stage lung cancer patients and when it is appropriate to integrate personalized therapies into the treatment regimen. We will also present an update on the results of recent clinical trials that suggest that maintenance chemotherapy prolongs survival in patients with advanced non-small cell lung cancer.

This conference is designed as a forum for discussion of advances in thoracic oncology that will help participants to stage, evaluate and recommend appropriate strategies for managing patients with advanced and early stage lung cancer, esophageal cancer and mesothelioma and enhance physicians' ability to counsel their patients about available treatments. There will be ample time for participants to ask questions and interact with the speakers. Participants are encouraged to submit interesting cases for discussion.

OBJECTIVES

After completing this activity, participants should be able to:

1. Apply the seventh edition AJCC/UICC TNM staging system to correctly stage patients with lung cancer or esophageal cancer.
2. Recommend appropriate management strategies for lung and esophageal cancer patients based on the seventh edition AJCC/UICC TNM staging system.
3. Evaluate the stage and cardiopulmonary status of patients in order to determine appropriate management strategies for mesothelioma patients.
4. Evaluate the risks/benefits of endoscopic therapy versus esophagectomy to determine appropriate management of patients with Barrett's high grade dysplasia (BHGD) and early esophageal cancer.
5. Assess advanced and early stage lung cancer patients to differentiate between those who should be managed with observation and long-term follow-up, those who should receive standard chemotherapy and when new tests should be ordered to identify patients who will benefit from personalized therapies.
6. Evaluate the benefits/risks of maintenance chemotherapy when developing treatment plans for patients with advanced NSCLC.
7. Compare the data from ongoing and recent personalized chemotherapy trials in patients with NSCLC to identify patients who will benefit.

TARGET AUDIENCE

This program is designed for medical and radiation oncologists, general and thoracic surgeons, pulmonologists, gastroenterologists, internists, family and general physicians and other physicians involved in the management of patients with lung cancer, mesothelioma and/or esophageal cancer. Fellows, residents, students, physician assistants, nurses, nurse practitioners, administrators, office managers, billers, coders, certified tumor registrars and other health professionals involved in the management of patients with lung cancer, mesothelioma and/or esophageal cancer may find the program beneficial.

ACCREDITATION STATEMENT

The Fox Chase Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Fox Chase Cancer Center designates this educational activity for a maximum of 9.25 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION AND PAYMENT

Send Registration Form and check payable to **Fox Chase Cancer Center**, Attn: Norma Gentner, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. **(Credit cards not accepted.)**

Registration Fees:

Includes program materials, continental breakfast, breaks and luncheon.

Physicians PA's/Nurses	Fellows Residents/Students	
\$100	\$50	Discounted Fee, Payment received by 2/15/2010
\$125	\$60	Registration Fee, Payment received by 3/25/2010
\$150	\$75	Onsite Fee, Payment received 3/26/2010
\$ 65		One-half day Fee, 7:55am-1:30pm or 12:35-6:00pm

Cancellations:

Cancellations received prior to March 19, 2010, will be refunded in full.

INQUIRIES

Office of Continuing Medical Education, Fox Chase Cancer Center
Telephone: **215-728-5358**; Fax: **215-214-8908**; E-mail: **CME@fccc.edu**

INTERESTING CASES

If you have an interesting case that you would like us to consider for discussion, please send a description of the case by **March 1, 2010** to the Office of CME, Email: **CME@fccc.edu**; Fax: **215-214-8908**.

DIRECTIONS/PARKING

Directions/Location Map are available at www.philadelphia.doubletree.com

PROGRAM

- 7:15 - 7:55 am **Registration and Continental Breakfast**
- 7:55 - 8:00 am **Welcome and Overview**
Walter J. Scott, MD, FACS

I. THORACIC CANCER STAGING SYMPOSIUM

LUNG CANCER

Moderator: Walter J. Scott, MD, FACS

- 8:00 - 8:15 am **Introduction and Case Presentation**
Walter J. Scott, MD, FACS

- 8:15 - 8:45 am **Changes to TNM Descriptors and Subsets**
Ramon Rami-Porta, MD

- 8:45 - 9:15 am **Nodal Staging: Correlating CT Images with the Lymph Node Map**
Barton N. Milestone, MD

- 9:15 - 9:45 am **Clinical Impact of the Staging System Changes**
Ramon Rami-Porta, MD

- 9:45 - 10:10 am **Question and Answer Panel with Case Presentation**
Moderator: Walter J. Scott, MD, FACS
Barton N. Milestone, MD
Ramon Rami-Porta, MD
George R. Simon, MD, FACP, FCCP

- 10:10 - 10:25 am **BREAK**

ESOPHAGEAL CANCER AND GE JUNCTION CANCER

Moderator: Abraham "Avi" Leberthal, MD, MHA

- 10:25-10:40 am **Introduction and Case Presentation**
Abraham "Avi" Leberthal, MD, MHA

PROGRAM (cont.)

- 10:40-11:10 am **Changes to TNM Descriptors and Subsets**
Thomas Rice, MD

- 11:10-11:40 am **Nodal Staging for Esophageal Cancer**
Abraham "Avi" Leberthal, MD, MHA

- 11:40-12:10 pm **Clinical Impact of the Staging System Changes**
(Including controversies regarding GE junction and gastric CA)
Thomas Rice, MD

- 12:10-12:35 pm **Question and Answer Panel with Case Presentation**
Abraham "Avi" Leberthal, MD, MHA and Thomas Rice, MD

- 12:35-1:30 pm LUNCH

- 1:00-1:30 pm **Mesothelioma Lecture:
Pretreatment Evaluation of the Mesothelioma Patient**
Abraham "Avi" Leberthal, MD, MHA

II. CLINICAL CONTROVERSY:

How do we treat the patient with Barrett's high-grade dysplasia (BHGD) and early esophageal cancer?

Moderator: Abraham "Avi" Leberthal, MD, MHA

- 1:30-1:45 pm **Introduction and Case Presentation**
Abraham "Avi" Leberthal, MD, MHA

- 1:45-2:15 pm **Endoscopic Therapies**
Jeffrey L. Tokar, MD

- 2:15-2:45 pm **Esophagectomy**
Thomas Rice, MD

continued on next page

PROGRAM (cont.)

2:45-3:10 pm **Case Review and Audience Participation Discussion**
Moderator: Abraham "Avi" Lebenthal, MD, MHA
Thomas Rice, MD and Jeffrey L. Tokar, MD

3:10-3:25 pm **BREAK**

III. PERSONALIZED TREATMENT FOR ADVANCED LUNG CANCER

Moderator: George R. Simon, MD, FACP, FCCP

3:15-3:30 pm **Introduction and Case Presentation**
George R. Simon, MD, FACP, FCCP

3:30-4:00 **Recent Advances in the Management of Advanced Stage NSCLC**
Chandra P. Belani, MD

4:00-4:30 **Chemotherapy for Early Stage Disease: Current Principles and Recommendations for Practice**
Mark A. Socinski, MD

4:30-5:00 **Current Status of Molecularly Tailored Therapies for NSCLC: A Primer and Update**
George R. Simon, MD, FACP, FCCP

5:00-5:30 **A Prelude To ASCO. What to Look for at ASCO 2010**
Corey J. Langer, MD, FACP

5:30-6:00 **Interactive Tumor Board: Case Presentations by Audience and Panelists**
Moderator: George R. Simon, MD, FACP, FCCP
Chandra P. Belani, MD
Corey J. Langer, MD, FACP
Mark A. Socinski, MD
Ramon Rami-Porta, MD
Walter J. Scott, MD, FACS

COURSE DIRECTOR

Walter J. Scott, MD, FACS

Gloria and Edmund M. Dunn Chair
Chief, Division of Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

COURSE CO-DIRECTORS

Abraham "Avi" Lebenthal, MD, MHA

Staff Surgeon
Division of Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

George R. Simon, MD, FACP, FCCP

Director, Thoracic Oncology
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

FACULTY

Chandra P. Belani, MD

Miriam Beckner Distinguished
Professor of Medicine
Penn State Department of Medicine
Deputy Director
Penn State Hershey Cancer Institute
Hershey, PA

Barton N. Milestone, MD

Vice Chairman
Department of Radiology
Director of MRI
Fox Chase Cancer Center
Philadelphia, PA

Corey J. Langer, MD, FACP

Director, Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Hematology/Oncology Division
University of Pennsylvania
Philadelphia, PA

Ramon Rami-Porta, MD

Attending Thoracic Surgeon
Thoracic Surgery Service
Hospital Universitario Mutua de Terrassa
Terrassa, Barcelona, Spain

Thomas Rice, MD

Daniel & Karen Lee Chair in Thoracic Surgery
Section Head, General Thoracic Surgery
Professor of Surgery,
Cleveland Clinic Lerner College of Medicine,
Case Western Reserve University
Cleveland, OH

Abraham "Avi" Lebenthal, MD, MHA

Staff Surgeon
Division of Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

continued on next page

FACULTY (cont.)

Walter J. Scott, MD, FACS

Gloria and Edmund M. Dunn Chair
Chief, Division of Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

George R. Simon, MD, FACP, FCCP

Director, Thoracic Oncology
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Mark A. Socinski, MD

Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC

Jeffrey L. Tokar, MD

Assistant Professor
Program Director, Interventional Endoscopy
Fellowship Program
Department of Medicine, GI Section
Fox Chase Cancer Center
Philadelphia, PA

FOX CHASE CANCER CENTER DISCLOSURE POLICY

It is the policy of Fox Chase Cancer Center to ensure that all sponsored continuing medical education activities are independently designed and produced and include valid content that is objective, balanced, free of commercial bias and in the best interest of the public. Fox Chase Cancer Center policy requires everyone in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest pertaining to the content of the activity. Individuals who refuse to disclose cannot have control of or responsibility for activity content. Conflicts of interest will be resolved prior to the activity. Fox Chase Cancer Center requires disclosure to the activity audience of relevant financial relationships of those with control over CME content and support from commercial interests.

REGISTRATION FORM ADVANCES IN THORACIC ONCOLOGY CONFERENCE

Name _____ Degree _____ Medical Specialty _____

(Please print/type name and degree as you would like them to appear on your nametag/certificate.)

Institution/Affiliation _____

Preferred Mailing Address _____

City _____ State _____ Zip _____

Daytime Phone _____ Fax _____ E-mail _____

Indicate if you are : Fellow Resident Medical School _____

Indicate FCCC Partner Affiliation _____

Specify questions/issues you would like speakers to address. _____

REGISTRATION AND PAYMENT

Send Registration Form & check payable to **Fox Chase Cancer Center**, Attn: Norma Gentner, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.
(Credit cards not accepted.)

Physicians/PAs/Nurses

- \$100
 \$125
 \$150
 \$ 65
 \$ 65

Fellows/Residents/Students

- \$50
 \$60
 \$75

Discounted Fee, Payment received by 2/15/2010

Registration Fee, Payment received 3/25/2010

Onsite Fee, Payment received 3/26/2010

One-half day Fee, **Morning**, 7:55am - 1:30pm

One-half day Fee, **Afternoon**, 12:35 pm - 6:00pm

Cancellations: Cancellations received prior to March 19, 2010, will be refunded in full.

SPECIAL NEEDS

ADA: If you require auxiliary aids or services as identified in the Americans with Disabilities Act, please specify: _____

Dietary: Kosher Vegetarian Other (Specify) _____